INOVIO Doses First Subject in Phase 2 Segment of its INNOVATE Phase 2/3 Clinical Trial for INO-4800, its DNA Medicine to Prevent COVID-19
- Monday, December 7, 2020, 8:03
- PR Newswire
- Add a comment
PLYMOUTH MEETING, Pa., Dec. 7, 2020 /PRNewswire/ — INOVIO (NASDAQ: INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases and cancer, today announced it has dosed its first subject in a Phase 2…
About the Author
admin has written 21717 stories on this site.